Discover the cure. One B-cell at a time.

CelliGO™— A new wave in antibody discovery.

Discover functional therapeutic antibodies with bioassays analyzing millions of B cells – one cell at a time.

Complexity – Simplified

The HiFiBiO difference

Functional therapeutic antibody discovery for important and challenging targets is enabled using droplet microfluidics. CelliGO™ allows ultra high throughput selection of antibodies from single B cells exhibiting functional modulation of a target cell.
silhouettes of different animal species
Species Agnostic
silhouettes of different animal species
In-Droplet Functional Assay
silhouettes of different animal species
VH/VL Paired Sequencing
silhouettes of different animal species
AbSolution Bioinformatics
silhouettes of different animal species
Rapid Cloning And Expression
silhouettes of different animal species
Validated Antibody Hits

Identify rare antibodies by a deep mining process delivering a diversity of validated hits within 5-6 weeks of sample harvest.

Click here to contact us

Leadership Team

Executive Management

  • Liang Schweizer, PhD (CEO)

    Liang Schweizer

    Liang Schweizer is the President and Chief Executive Officer at HiFiBiO, with 31 years of biomedical research experience, including 15 years in drug discovery and development.


    Previously, she co-founded Harbour BioMed and served as its CSO. Prior to her entrepreneurial career, Liang served as a Senior Director, Head of Asian Cancer Research at Sanofi, and as a steering committee member for global oncology. Before that, she was a director in Leads Discovery and Optimization (LDO) at Bristol Myers Squibb Company.

    Liang graduated from the University of Science and Technology of China (USTC) majoring in Biology. She received her Master’s degree in Microbial Engineering at the University of Minnesota and earned her PhD. in Molecular Biology from the University in Zurich, Switzerland. Her postdoctoral training was with Dr. Harold Varmus, a Nobel Laureate, at Memorial Sloan Kettering Cancer Center (MSKCC), New York.

  • Jeff He, MBA (COO)

    Jeff Ho

    Jeff He is the Chief Operations Officer at HiFiBiO, with over 20 years of experience in finance, corporate strategy, and operations.


    Previously, he co-founded Harbour BioMed and served as its Chief Financial Officer. Before that, he was the Executive Vice President of ShangPharma/ChemPartner, a leading contract research organization (CRO) based in Shanghai. Jeff also served as Senior Vice President at Texas Pacific Group (TPG), where he helped to privatize ShangPharma from the NYSE. Prior to TPG, Jeff held management roles with increasing P&L responsibilities at Danaher/Fluke and Saint-Gobain. In his early career, he was a strategy consultant at Bain & Company and a senior financial analyst at Intel.

    Jeff received his MBA degree from Goizueta Business School at Emory University and his bachelor degree in engineering from Zhejiang University.

  • Fred Dom, M.Sc. (Director, France)

    Fred Dom

    Fred Dom is a serial entrepreneur with expertise in private capital investment and operations. He is the co-founder of HiFiBiO and now serves as its Director of French Operations.


    Previously, he was CEO of FlexGen (Leiden, the Netherlands) where he spearheaded a commercialization strategy resulting in a successful financing and launch of new, revenue-generating products.

    Prior to FlexGen, Fred was CEO and co-founder of RSP Technology BV, a world-leading supplier of aluminum superalloys to the defense, automotive, aerospace and electronics industries based on a proprietary process exclusively licensed from Delft University.

    Fred began his career at Rijnvelden BV, focusing on investment in early stage technology companies. Fred chairs the Dutch grant advisory committee to the Ministry of Economic Affairs in the field of innovation and entrepreneurship (total budget € 80 million) and he is a member of the “Regiegroep”—14 industrial and academic thought leaders in Dutch Life Science industry. This high profile group is appointed by the Minister of Economic Affairs, to develop a new industry vision and recommend new policies to support the Dutch Life Science & Health industry (Topsectorplan). Fred holds a B.Sc. and M.Sc. from Erasmus University.

  • Colin Brenan, Ph.D. (CCO)

    Colin Brenan

    Colin Brenan is a serial life sciences entrepreneur and is the Chief Commercial Officer and co-founder of HiFiBiO.


    Formerly he was Managing Director of the Monsanto-Atlas Seed Fund Alliance at Atlas Venture (Cambridge, USA) and prior to Atlas he was Director of Strategic Relationships for the Partners HealthCare (Boston, USA) Center for Integration of Medicine and Innovative Technology (CIMIT). Previous to CIMIT, he was the Founder, Chief Technology Officer and Senior Vice President, Business Development for BioTrove Inc. (Woburn, USA), a life science tools and consumables company spun-out from the Massachusetts Institute of Technology (MIT) and acquired by Life Technologies Inc. (NASDAQ:LIFE); and a Founder of Biocius Inc., a drug development instrument and service provider spun-out from BioTrove and acquired by Agilent Inc. (NYSE:A).

    Colin received his B.Sc. (Honors Physics), M. Eng. (Electrical), and Ph.D. (Biomedical Engineering) from McGill University (Montreal, Canada) and completed a NSERC post-doctoral fellowship at MIT (Cambridge, USA).

Scientific Founders

  • Prof. Andrew Griffiths

    Andrew Griffiths is a Professor of Biochemistry at École Supérieure de Chimie Industrielles de Paris (ESPCI) in Paris.


    Prof Griffiths is formerly the holder of a Chaire d’Excellence from the Ministère pour la Recherche, France, at the Institut de Science et d’Ingénierie Supramoléculaires (ISIS) in Strasbourg. After receiving a B.Sc. in Biochemistry (First Class) from the University of Sheffield in 1985 and a Ph.D. from the University of Leicester, in 1988, he joined Greg Winter at the MRC Laboratory of Molecular Biology (LMB), Cambridge where he co-developed phage-display for the selection of human antibodies for therapy, first as a Post Doc. (1989-1990) and later as a Cancer Research Campaign Fellow (1991-1995).

    This work led directly to the creation of two companies, Cambridge Antibody Technology (acquired by AstraZeneca for $1.32 billion) and Domantis (acquired by GSK for $0.45 billion), and several blockbuster drugs including Humira® and Benlysta®. His current work is in the development of droplet-based microfluidic systems for directed evolution of enzymes, high-throuhgput screening for drug discovery, and diagnostic applications. Andrew is a founder of RainDance Technologies.

  • Prof. Jérôme Bibette

    Jérôme Bibette is the Professor of soft matter physics at École Supérieure de Chimie Industrielles de Paris (ESPCI).


    Jérôme is the co-director of the Michelin Advanced Research Initiative at ESPCI and is best known for his work in the areas of emulsions and superparamagnetic colloids, microfluidics, rheology, fluid mechanics, colloid chemistry, biophysics, complex fluids, soft condensed matter physics and phase transitions. He received his PhD in physical chemistry from Bordeaux University and worked as an associate professor at Bordeaux, prior to joining the faculty at ESPCI. Jerome is a Founder of RainDance Technologies, Ademtech and Capsum.

  • Prof. David Weitz

    Dave Weitz is the Mallinckrodt Professor of Physics & Applied Physics and professor of Systems Biology at Harvard University.


    Dave is the co-director of the BASF Advanced Research Initiative at Harvard, co-director of the Harvard Kavli Institute for BioNano Science & Technology, and director of the Harvard Materials Research Science & Engineering Center. He is best known for his work in the areas of diffusing-wave spectroscopy, microrheology, microfluidics, rheology, fluid mechanics, interface and colloid science, colloid chemistry, biophysics, complex fluids, soft condensed matter physics, phase transitions, the study of glass and amorphous solids, liquid crystals, self-assembly, surface-enhanced light scattering, and diffusion-limited aggregation.

    He received his PhD in superconductivity from Harvard and worked as a research physicist at Exxon Research and Engineering for nearly 18 years, prior to becoming a Professor of Physics at the University of Pennsylvania, before moving to Harvard in 1999. Dave is a Founder of RainDance Technologies, GnuBIO and Capsum. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences.

  • Dr. Robert Nicol

    Rob Nicol is director of the Technology Labs at the Broad Institute of MIT and Harvard.


    Under Rob’s guidance, the Technology Labs serve as an advanced R&D group within the institute integrating capabilities in molecular biology, bio-engineering, synthetic biology, microfluidics, bio-informatics, and industrial process design to meet the needs of the Broad community. Rob is also co-founder of the MIT-Broad Foundry for Synthetic Biology.

    Rob joined the Whitehead Institute / MIT Center for Genome Research in 2001 to apply industrial process design to genome sequencing and directed the Sequencing Operations and Technology Development groups at the Broad for over 12 years, designing and implementing multiple generations of high-throughput DNA sequencing processes.

    Earlier, as an MIT Leaders for Manufacturing Fellow, Rob worked on production line optimization for Raytheon’s AMRAAM missile and Boeing’s 777. Rob previously worked as a project manager for Fluor Corporation, where he managed multiple, large-scale petrochemical design and construction projects.

    Rob received his B.S. in mechanical engineering from the University of Houston, and an M.S. in chemical engineering, M.B.A., and Ph.D. in engineering systems from MIT.

  • Prof. Bradley Bernstein

    Bradley Bernstein is a Professor of Pathology at the Massachusetts General Hospital and Harvard Medical School and an Early Career Scientist of the Howard Hughes Medical Institute.


    Brad co-directs the Broad Institute’s Epigenomics Program and oversees data production centers for the ENCODE project and the NIH Common Fund for Epigenomics. His research focuses on epigenetics—changes in gene activity governed by influences outside the genes themselves—and specifically how the organization of genomic DNA into chromatin influences development and disease. His work is notable for the discovery of epigenetic mechanisms in pluripotent stem cells and for the systematic annotation of enhancer-like elements in the human genome that coincide with DNA sequence variants associated with human diseases.

    Brad received his B.S. in Physics from Yale University and his M.D. and Ph.D. from the University of Washington School of Medicine. He completed a residency in clinical pathology at Brigham and Women’s Hospital and carried out postdoctoral research at Harvard University. Bernstein’s honors and awards include a Career Award in the Biomedical Sciences from the Burroughs Wellcome Fund, a junior faculty award from the Culpeper Foundation, an Early Achievement Award from the University of Washington Alumni Association, the Howard Goodman Award, and the Martin Prize for Basic Science from the Massachusetts General Hospital.


In the News